We were really happy to meet you at the Biotechnica 2015 in Hannover, Germany, from 6th to 8th of October, a trade fair that covers the complete value-adding chain in biotechnology - from basic research to finished product.
Our Cellab Team took part in the Biotechnologietage 2015 in Cologne, Germany, the 22nd and 23rd of April, an annual German forum about the biotechnology industry.
In the near future, stem cell therapies, especially allogeneic therapies (when donor and patient are not the same person), will help cure a variety of acute and chronic diseases. There are hundreds of ongoing clinical trials to validate this new therapeutic approach. For allogeneic therapies, stem cells are acquired from a universal donor and therefore suitable for large-scale manufacturing. Cell proliferation technologies for these types of cell therapies need new innovations to enable the manufacturing consistency of cell therapy products.
Regenerative medicine is experiencing a transition from niche experiments to more standardized clinical therapies. Cellab can provide you with a high degree of control of any lab scale bioreactor. For instance, in the case of mesenchymal stem cell (MSC) based treatments, if the cell therapy works, the cell source, composition and production will be the primary differentiation factors. However, for the clinical trials, the quality of the cells is the highest priority for successful cellular-based regenerative medicine applications.